Concert Pharmaceuticals (NASDAQ:CNCE) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, ValuEngine reports.

Several other analysts have also recently weighed in on the stock. Janney Montgomery Scott reaffirmed a “buy” rating and set a $10.00 price objective (down from $13.00) on shares of Concert Pharmaceuticals in a research note on Monday, September 30th. HC Wainwright decreased their price objective on shares of Concert Pharmaceuticals from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. BidaskClub cut shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, September 28th. Stifel Nicolaus cut shares of Concert Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $18.00 to $8.00 in a research note on Friday, September 27th. Finally, Mizuho reaffirmed a “buy” rating and set a $18.00 price objective on shares of Concert Pharmaceuticals in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $15.31.

NASDAQ:CNCE opened at $7.48 on Tuesday. Concert Pharmaceuticals has a 12-month low of $5.36 and a 12-month high of $17.83. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $179.76 million, a PE ratio of -3.12 and a beta of 0.98. The firm has a 50-day moving average price of $6.62 and a 200 day moving average price of $9.38.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.85) by $0.13. Concert Pharmaceuticals had a negative net margin of 7,291.37% and a negative return on equity of 55.06%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.35 million. On average, research analysts expect that Concert Pharmaceuticals will post -3.21 EPS for the current year.

In other news, Director Heek Christi Van acquired 5,000 shares of the firm’s stock in a transaction on Tuesday, October 8th. The shares were purchased at an average cost of $5.90 per share, with a total value of $29,500.00. Following the completion of the purchase, the director now owns 5,000 shares of the company’s stock, valued at $29,500. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 11.00% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CNCE. Quantamental Technologies LLC bought a new stake in shares of Concert Pharmaceuticals during the second quarter valued at approximately $27,000. Flagship Harbor Advisors LLC grew its stake in shares of Concert Pharmaceuticals by 163.2% during the third quarter. Flagship Harbor Advisors LLC now owns 5,000 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,100 shares during the last quarter. Aperio Group LLC bought a new stake in shares of Concert Pharmaceuticals during the second quarter valued at approximately $43,000. Virtu Financial LLC bought a new stake in shares of Concert Pharmaceuticals during the third quarter valued at approximately $69,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Concert Pharmaceuticals during the second quarter valued at approximately $128,000. 65.88% of the stock is currently owned by institutional investors and hedge funds.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

Featured Article: Investing in Dividend Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.